Research Papers:
Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach
PDF | Full Text | Supplementary Files | How to cite
Metrics: PDF 1292 views | Full Text 2674 views | ?
Abstract
Pooja Gulhane1, Prajakta Nimsarkar1, Komal Kharat1 and Shailza Singh1
1 National Centre for Cell Science, NCCS Complex, Ganeshkhind, SP Pune University Campus, Pune 411007, India
Correspondence to:
Shailza Singh, | email: | [email protected] |
Keywords: non-small cell lung cancer; miRNAs; miR-520c-3p; PI3K/AKT signaling pathway; therapeutic targeting
Received: December 13, 2021 Accepted: May 03, 2022 Published: May 24, 2022
ABSTRACT
Background: Non-small cell lung cancer (NSCLC) is considered to have more than 80% of all lung cancer cases, making it the leading cause of cancer-related deaths globally. MicroRNA (miRNA) deregulation has been seen often in NSCLC and has been linked to the disease’s genesis, progression, and metastasis via affecting their target genes.
Materials and Methods: Our study focused on the functionality of down-regulated miRNAs in NSCLC. For this study, we used 91 miRNAs reported to be down-regulated in NSCLC. The targets of these miRNAs were chosen from miRNA databases with functionality in NSCLC, including miRBase, miRDB, miRTV, and others. Inter-regulatory miRNA-NSCLC networks were generated. Simulated annealing was used to improve the network’s resilience and understandability. GSEA was used to examine 24607 genes reported experimentally in order to gain physiologically relevant information about the target miR-520c-3p.
Results: The study revealed functional prominence on miR-520c-3p, down-regulated during NSCLC. The involvement of miR-520c-3p in the PI3K/AKT/mTOR signaling pathway was recognized.
Conclusions: The therapeutic usage by designing a synthetic circuit of miR-520c-3p was explored, which may help in suppressing tumors in NSCLC. Our study holds promise for the successful deployment of currently proposed miRNA-based therapies for malignant disorders, which are still in the early pre-clinical stages of development.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28233